Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia

Sung Eun Lee; Soo Young Choi; Yun Jeong Oh; Soo Hyun Kim; Hye Young Song; Hea Lyun Yoo; Mi Young Lee; Moon Jung Chae; Ki Hoon Kang; Hee Jeong Hwang; Eun Jung Jang; Dong Wook Kim

doi:10.1016/j.leukres.2015.01.011

Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia

Sung Eun Lee
, Soo Young Choi
, Yun Jeong Oh
, Soo Hyun Kim
, Hye Young Song
, Hea Lyun Yoo
, Mi Young Lee
, Moon Jung Chae
, Ki Hoon Kang
, Hee Jeong Hwang
, Eun Jung Jang
, Dong Wook Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

To explore the factors for achieving early molecular responses (EMR; BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months) by imatinib (IM), baseline characteristics including individual BCR-ABL1 transcript level, dose intensity, and IM trough level on day 29 were analyzed in 286 chronic phase chronic myeloid leukemia patients. Distinct predictive factors for achieving EMR at 3 months and 6 months were noted. Blast count at diagnosis and IM trough level on day 29 were significantly associated with an achievement of 3-month EMR. Early decline of BCR-ABL1 transcript, low Sokal risk, and mean daily dose (≥350. mg/day) by 6 months were associated with an achievement of 6-month EMR. Understanding the predictive factors for EMR may provide additional information to guide clinical decisions on the changing therapies at each landmark.

Original language	English
Pages (from-to)	411-418
Number of pages	8
Journal	Leukemia Research
Volume	39
Issue number	4
DOIs	https://doi.org/10.1016/j.leukres.2015.01.011
State	Published - 1 Apr 2015

Bibliographical note

Publisher Copyright:
© 2015 .

Keywords

Chronic myeloid leukemia
Early molecular response
Imatinib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2015.01.011

Cite this

Lee, S. E., Choi, S. Y., Oh, Y. J., Kim, S. H., Song, H. Y., Yoo, H. L., Lee, M. Y., Chae, M. J., Kang, K. H., Hwang, H. J., Jang, E. J., & Kim, D. W. (2015). Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia. Leukemia Research, 39(4), 411-418. https://doi.org/10.1016/j.leukres.2015.01.011

@article{7b4f34de7767430c927f54bcbea9b689,

title = "Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia",

abstract = "To explore the factors for achieving early molecular responses (EMR; BCR-ABL1 ≤10\% at 3 months, ≤1\% at 6 months) by imatinib (IM), baseline characteristics including individual BCR-ABL1 transcript level, dose intensity, and IM trough level on day 29 were analyzed in 286 chronic phase chronic myeloid leukemia patients. Distinct predictive factors for achieving EMR at 3 months and 6 months were noted. Blast count at diagnosis and IM trough level on day 29 were significantly associated with an achievement of 3-month EMR. Early decline of BCR-ABL1 transcript, low Sokal risk, and mean daily dose (≥350. mg/day) by 6 months were associated with an achievement of 6-month EMR. Understanding the predictive factors for EMR may provide additional information to guide clinical decisions on the changing therapies at each landmark.",

keywords = "Chronic myeloid leukemia, Early molecular response, Imatinib",

author = "Lee, \{Sung Eun\} and Choi, \{Soo Young\} and Oh, \{Yun Jeong\} and Kim, \{Soo Hyun\} and Song, \{Hye Young\} and Yoo, \{Hea Lyun\} and Lee, \{Mi Young\} and Chae, \{Moon Jung\} and Kang, \{Ki Hoon\} and Hwang, \{Hee Jeong\} and Jang, \{Eun Jung\} and Kim, \{Dong Wook\}",

note = "Publisher Copyright: {\textcopyright} 2015 .",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.leukres.2015.01.011",

language = "English",

volume = "39",

pages = "411--418",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia

AU - Lee, Sung Eun

AU - Choi, Soo Young

AU - Oh, Yun Jeong

AU - Kim, Soo Hyun

AU - Song, Hye Young

AU - Yoo, Hea Lyun

AU - Lee, Mi Young

AU - Chae, Moon Jung

AU - Kang, Ki Hoon

AU - Hwang, Hee Jeong

AU - Jang, Eun Jung

AU - Kim, Dong Wook

PY - 2015/4/1

Y1 - 2015/4/1

N2 - To explore the factors for achieving early molecular responses (EMR; BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months) by imatinib (IM), baseline characteristics including individual BCR-ABL1 transcript level, dose intensity, and IM trough level on day 29 were analyzed in 286 chronic phase chronic myeloid leukemia patients. Distinct predictive factors for achieving EMR at 3 months and 6 months were noted. Blast count at diagnosis and IM trough level on day 29 were significantly associated with an achievement of 3-month EMR. Early decline of BCR-ABL1 transcript, low Sokal risk, and mean daily dose (≥350. mg/day) by 6 months were associated with an achievement of 6-month EMR. Understanding the predictive factors for EMR may provide additional information to guide clinical decisions on the changing therapies at each landmark.

AB - To explore the factors for achieving early molecular responses (EMR; BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months) by imatinib (IM), baseline characteristics including individual BCR-ABL1 transcript level, dose intensity, and IM trough level on day 29 were analyzed in 286 chronic phase chronic myeloid leukemia patients. Distinct predictive factors for achieving EMR at 3 months and 6 months were noted. Blast count at diagnosis and IM trough level on day 29 were significantly associated with an achievement of 3-month EMR. Early decline of BCR-ABL1 transcript, low Sokal risk, and mean daily dose (≥350. mg/day) by 6 months were associated with an achievement of 6-month EMR. Understanding the predictive factors for EMR may provide additional information to guide clinical decisions on the changing therapies at each landmark.

KW - Chronic myeloid leukemia

KW - Early molecular response

KW - Imatinib

UR - https://www.scopus.com/pages/publications/84925209944

U2 - 10.1016/j.leukres.2015.01.011

DO - 10.1016/j.leukres.2015.01.011

M3 - Article

C2 - 25680524

AN - SCOPUS:84925209944

SN - 0145-2126

VL - 39

SP - 411

EP - 418

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this